Hong Kong Software Stock News

United Laboratories International Holdings recently reported that its wholly owned Zhongshan branch of Zhuhai United Laboratories received China National Medical Products Administration approval, with quality and efficacy consistency evaluation, for its 2.0g Cefoperazone Sodium and Sulbactam Sodium for Injection, already classified as a Category B drug in the 2024 National Medical Insurance Drug List. This outcome strengthens the company’s anti-infective portfolio by validating a...

GoFintech Quantum Innovation (SEHK:290) just flipped its half year results from a small loss to a net profit, and that earnings swing is quickly becoming the main story behind the stock’s recent momentum. See our latest analysis for GoFintech Quantum Innovation. That earnings swing helps explain why the share price has climbed to HK$2.29, with a powerful year to date share price return of 186.25% and a remarkable three year total shareholder return of 1,599.01%, suggesting momentum is still...

Xiaomi (SEHK:1810) just posted a standout third quarter, with several metrics hitting record highs and its Cars unit delivering a breakthrough as smart electric vehicle and innovation revenue surged more than 199% year over year. See our latest analysis for Xiaomi. The upbeat quarter has helped Xiaomi regain some investor confidence, with the latest HK$42.78 share price sitting against a solid year to date share price return. A powerful three year total shareholder return above 270% suggests...

New World Development (SEHK:17) has just wrapped up a major debt exchange, issuing about USD 1.36 billion in new bonds and cutting its debt load by nearly 50%, a meaningful shift for equity holders. See our latest analysis for New World Development. The sizeable debt cut seems to have given sentiment a lift, with a 1 day share price return of 4.87% helping extend its year to date share price return of 41.07%. However, the 3 year total shareholder return is still deeply negative at 62.10%. If...

Lygend Resources & Technology (SEHK:2245) has called an Extraordinary General Meeting for December 19, 2025, to seek approval for related party transactions, a move that puts governance and transparency squarely in focus for shareholders. See our latest analysis for Lygend Resources & Technology. The governance spotlight from this Extraordinary General Meeting comes after a sharp run up, with the 188.52% year to date share price return and 147.95% one year total shareholder return suggesting...

CSPC Pharmaceutical Group (SEHK:1093) just cleared two regulatory hurdles, securing trial approvals in China and the US for first in class obesity and kidney disease candidates, giving investors fresh, data-driven reasons to revisit the stock. See our latest analysis for CSPC Pharmaceutical Group. These back to back trial greenlights land at a time when CSPC Pharmaceutical Group’s 1 year total shareholder return of 58.59 percent contrasts sharply with a weak 90 day share price return of...

HSBC Global Research has just spotlighted Harbin Electric (SEHK:1133), highlighting its role in nuclear and hydropower supply as China wrestles with energy oversupply and fast rising demand from AI driven data centers. See our latest analysis for Harbin Electric. The HSBC call lands on a stock that has already been on a tear, with a roughly 66% 3 month share price return and a near fivefold 1 year total shareholder return, suggesting momentum is still very much intact despite only modest...

Onewo (SEHK:2602) just put a clear marker down by kicking off a buyback of up to 10% of its H shares, signaling confidence in its long term outlook and capital discipline. See our latest analysis for Onewo. The buyback news lands after a choppy stretch, with a 30 day share price return of minus 11.07% and a three year total shareholder return of minus 55.31%. Management is clearly trying to reset sentiment and rebuild momentum. If this kind of opportunistic capital return has you thinking...

Ascentage Pharma Group International (SEHK:6855) has quietly outperformed over the past year, and with shares up roughly 56% in that time, investors are starting to revisit the story behind this clinical stage biotech. See our latest analysis for Ascentage Pharma Group International. The stock has been choppy in recent months, with a 1 day share price return of 4.44 percent and a 90 day share price return of minus 19.91 percent. However, a 1 year total shareholder return of 55.76 percent...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

In late November 2025, Ascletis Pharma announced it had selected ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist developed with its POTENT and AI-assisted technologies, as a clinical development candidate and outlined plans to file a US FDA Investigational New Drug application for obesity treatment in 2026. The company highlighted that ASC37 showed much higher in vitro potency and substantially improved oral bioavailability versus existing incretin drugs in non-human primate studies,...

Earlier this month, a coalition of major Chinese state-owned enterprises and academic institutions, including China Petroleum & Chemical Corp. (Sinopec), launched an initiative to promote dimethyl ether (DME) as a cleaner and safer next-generation marine fuel, targeting advances in production, engine systems, refueling infrastructure, and safety standards. This alliance positions Sinopec at the center of efforts to accelerate low-emission shipping fuels, potentially reinforcing its role in...

There wouldn't be many who think Swire Pacific Limited's ( HKG:19 ) price-to-sales (or "P/S") ratio of 1x is worth a...

There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a...

Despite an already strong run, China Wantian Holdings Limited ( HKG:1854 ) shares have been powering on, with a gain of...

Acme International Holdings Limited ( HKG:1870 ) shares have continued their recent momentum with a 26% gain in the...

Key Insights Viva Goods' significant individual investors ownership suggests that the key decisions are influenced by...

When you see that almost half of the companies in the Chemicals industry in Hong Kong have price-to-sales ratios (or...

Kowloon Development Company Limited ( HKG:34 ) is about to trade ex-dividend in the next three days. The ex-dividend...

While Puxing Energy Limited ( HKG:90 ) shareholders are probably generally happy, the stock hasn't had particularly...

Investors may wish to note that an insider of Shanghai Gench Education Group Limited , Xiangzhan Zheng, recently netted...

Want Want China Holdings (SEHK:151) just posted mixed half year earnings, with sales edging higher but net income and earnings per share slipping, giving investors a tricky read on underlying profitability. See our latest analysis for Want Want China Holdings. The latest half year numbers land after a choppy stretch for the shares, with a 7 day share price return of 5.36 percent but a 90 day share price return of negative 11.69 percent. The 1 year total shareholder return of 14.60 percent...

Earlier in December 2025, FIT Hon Teng Limited announced that it would postpone the dispatch of a circular on framework agreements and related transactions from December 5 to December 16, 2025, to complete the necessary information. This extra preparation time highlights how documentation quality and disclosure timing can affect shareholder expectations around upcoming deals and corporate actions. We’ll explore how the delayed circular on framework agreements could shape FIT Hon Teng’s...

Country Garden Holdings said that in early December 2025 the court sanctioned its offshore debt restructuring scheme, while bondholders approved changes to nine onshore corporate bonds and shareholders backed loan capitalisation, new share issuance, and a management incentive plan at an extraordinary general meeting. Together with November 2025 contracted sales of about RMB 2.35 billion and leadership changes including a new Co‑Chairman, these steps show the group reshaping its balance sheet...